JP2014503475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503475A5 JP2014503475A5 JP2013535421A JP2013535421A JP2014503475A5 JP 2014503475 A5 JP2014503475 A5 JP 2014503475A5 JP 2013535421 A JP2013535421 A JP 2013535421A JP 2013535421 A JP2013535421 A JP 2013535421A JP 2014503475 A5 JP2014503475 A5 JP 2014503475A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- disease
- liposome
- terminus
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 66
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 52
- 201000010099 disease Diseases 0.000 claims description 41
- 239000002502 liposome Substances 0.000 claims description 40
- 208000035475 disorder Diseases 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 15
- 230000000890 antigenic effect Effects 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 12
- 230000002209 hydrophobic effect Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 206010020751 Hypersensitivity Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 238000009825 accumulation Methods 0.000 claims description 8
- 230000002776 aggregation Effects 0.000 claims description 8
- 238000004220 aggregation Methods 0.000 claims description 8
- 230000007815 allergy Effects 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- -1 diglycerides Chemical class 0.000 claims description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 238000011321 prophylaxis Methods 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 241000282412 Homo Species 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 4
- 229930186217 Glycolipid Natural products 0.000 claims description 4
- 239000000232 Lipid Bilayer Substances 0.000 claims description 4
- 235000021314 Palmitic acid Nutrition 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 108091005601 modified peptides Proteins 0.000 claims description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 150000003408 sphingolipids Chemical class 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- 230000003381 solubilizing effect Effects 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000012474 protein marker Substances 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 11
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical group O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 4
- LJUIOEFZFQRWJG-GHYFRYPYSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2r)-2-amino-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)CSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O LJUIOEFZFQRWJG-GHYFRYPYSA-N 0.000 description 2
- OEDPHAKKZGDBEV-GFPBKZJXSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2r)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CCCCCCCCCCCCCCC)CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC OEDPHAKKZGDBEV-GFPBKZJXSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 208000021550 spleen neoplasm Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10188832.9 | 2010-10-26 | ||
| EP10188832 | 2010-10-26 | ||
| PCT/EP2011/068797 WO2012055933A1 (en) | 2010-10-26 | 2011-10-26 | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503475A JP2014503475A (ja) | 2014-02-13 |
| JP2014503475A5 true JP2014503475A5 (enExample) | 2014-10-16 |
| JP6027011B2 JP6027011B2 (ja) | 2016-11-16 |
Family
ID=44872345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535421A Active JP6027011B2 (ja) | 2010-10-26 | 2011-10-26 | 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9687447B2 (enExample) |
| EP (1) | EP2632434B1 (enExample) |
| JP (1) | JP6027011B2 (enExample) |
| KR (1) | KR101854943B1 (enExample) |
| CN (1) | CN103189050B (enExample) |
| AR (1) | AR083561A1 (enExample) |
| AU (1) | AU2011322553B2 (enExample) |
| CA (1) | CA2813833C (enExample) |
| TW (1) | TW201223561A (enExample) |
| WO (1) | WO2012055933A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140314837A1 (en) * | 2011-09-23 | 2014-10-23 | Ac Immune S. A. | Vaccine Therapy |
| KR20160042917A (ko) | 2013-07-25 | 2016-04-20 | 엑시큐어, 인크. | 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물 |
| CN103601796B (zh) * | 2013-11-11 | 2016-09-21 | 杭州璞题生物科技有限公司 | 亨廷顿蛋白的棕榈化修饰方法 |
| JP6527516B2 (ja) | 2013-12-03 | 2019-06-05 | ノースウェスタン ユニバーシティ | リポソーム粒子、前述のものを作製する方法及びその使用 |
| JP6019254B2 (ja) | 2014-04-23 | 2016-11-02 | 株式会社ニチレイバイオサイエンス | 標的マーカー検出用組合せ物 |
| EP3164113B1 (en) * | 2014-06-04 | 2019-03-27 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| WO2016028940A1 (en) | 2014-08-19 | 2016-02-25 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| EA201790802A1 (ru) | 2014-10-06 | 2017-08-31 | Экзикьюр, Инк. | Соединения против tnf |
| US20200297867A1 (en) * | 2016-02-01 | 2020-09-24 | Exicure, Inc. | Surface functionalization of liposomes and liposomal spherical nucleic acids (snas) |
| JP7186094B2 (ja) | 2016-05-06 | 2022-12-08 | イグジキュア オペレーティング カンパニー | インターロイキン１７受容体ｍＲＮＡの特異的ノックダウンのためのアンチセンスオリゴヌクレオチド（ＡＳＯ）を提示するリポソーム系球状核酸（ＳＮＡ）構築物 |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| JP2020526558A (ja) | 2017-07-13 | 2020-08-31 | ノースウェスタン ユニバーシティ | オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法 |
| EA202091012A1 (ru) * | 2017-10-25 | 2020-08-27 | Янссен Фармасьютикалз, Инк. | Композиции фосфорилированных тау-пептидов и их применения |
| CA3086879A1 (en) | 2018-01-05 | 2019-07-11 | Ac Immune Sa | Misfolded tdp-43 binding molecules |
| CN112165956A (zh) * | 2018-04-10 | 2021-01-01 | Ac免疫有限公司 | 抗Aβ治疗性疫苗 |
| PE20201344A1 (es) * | 2018-04-10 | 2020-11-25 | Ac Immune Sa | Vacunas terapeuticas anti-abeta |
| WO2020023445A1 (en) * | 2018-07-24 | 2020-01-30 | Taiwan Liposome Co., Ltd. | Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof |
| US12016885B2 (en) | 2018-11-06 | 2024-06-25 | Alsatech, Inc. | Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab |
| CN113710269A (zh) | 2019-02-08 | 2021-11-26 | Ac免疫有限公司 | 磷酸化Tau肽疫苗的安全施用方法 |
| KR20210154179A (ko) | 2019-04-18 | 2021-12-20 | 에이씨 이뮨 에스.에이. | 치료 및 진단용 신규한 분자 |
| MA55902A (fr) * | 2019-04-24 | 2022-03-16 | Ac Immune Sa | Administration hétérologue de vaccins tau |
| EP3972633A1 (en) | 2019-05-21 | 2022-03-30 | AC Immune SA | Anti-abeta vaccine therapy |
| US12600766B2 (en) | 2019-05-23 | 2026-04-14 | Ac Immune Sa | Anti-TDP-43 binding molecules and uses thereof |
| CA3149837A1 (en) * | 2019-09-10 | 2021-03-18 | Oskar Adolfsson | Novel molecules for diagnosis |
| US12319711B2 (en) | 2019-09-20 | 2025-06-03 | Northwestern University | Spherical nucleic acids with tailored and active protein coronae |
| US12378560B2 (en) | 2019-10-29 | 2025-08-05 | Northwestern University | Sequence multiplicity within spherical nucleic acids |
| US20250340623A1 (en) | 2019-12-04 | 2025-11-06 | Ac Immune Sa | Novel Molecules for Therapy and Diagnosis |
| WO2021174075A1 (en) * | 2020-02-27 | 2021-09-02 | Adeptrix Corp. | Multiplexed bead-based analytical assays |
| WO2022003443A1 (ko) * | 2020-06-30 | 2022-01-06 | 아이진 주식회사 | 양이온성 리포좀을 포함하는 사포닌의 용혈 억제용 조성물 |
| US20230322908A1 (en) | 2020-08-14 | 2023-10-12 | Ac Immune Sa | Humanized Anti-TDP-43 Binding Molecules and Uses Thereof |
| US20250320283A1 (en) | 2020-10-16 | 2025-10-16 | Ac Immune Sa | Antibodies Binding to Alpha-Synuclein for Therapy and Diagnosis |
| MX2024009948A (es) | 2022-02-16 | 2024-08-22 | Ac Immune Sa | Moleculas de union anti-tdp-43 humanizadas y usos de las mismas. |
| KR20250004705A (ko) | 2022-04-08 | 2025-01-08 | 에이씨 이뮨 에스에이 | 항-tdp-43 결합 분자 |
| KR20250137159A (ko) | 2023-01-26 | 2025-09-17 | 에이씨 이뮨 에스에이 | 항-a베타 백신 요법 |
| AU2024211543A1 (en) | 2023-01-26 | 2025-07-17 | Ac Immune Sa | Liposomal construct |
| JP2026509262A (ja) | 2023-03-08 | 2026-03-17 | エイシー イミューン ソシエテ アノニム | 抗ｔｄｐ－４３結合分子およびその使用 |
| WO2025196262A1 (en) | 2024-03-22 | 2025-09-25 | Ac Immune Sa | Immunoassay involving antibodies binding vaccine adjuvants |
| WO2026013218A1 (en) | 2024-07-10 | 2026-01-15 | Ac Immune Sa | Anti-tdp-43 vectors, binding molecules and uses thereof |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4565696A (en) | 1983-08-03 | 1986-01-21 | The Regents Of The University Of California | Production of immunogens by antigen conjugation to liposomes |
| DE3683688D1 (de) | 1985-04-19 | 1992-03-12 | Wistar Inst | Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort. |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5620689A (en) | 1989-10-20 | 1997-04-15 | Sequus Pharmaceuuticals, Inc. | Liposomes for treatment of B-cell and T-cell disorders |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5434050A (en) | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| WO1993017715A1 (en) | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
| US6093399A (en) | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
| US5877289A (en) | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
| US6036955A (en) | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
| US6004555A (en) | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| IT1257893B (it) | 1992-06-17 | 1996-02-16 | Ist Superiore Sanita | Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana. |
| EP0652775B1 (en) | 1992-07-27 | 2000-04-19 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Targeting of liposomes to the blood-brain barrier |
| AU5420494A (en) * | 1992-11-02 | 1994-05-24 | Yves Claude Nicolau | Method of reducing multidrug resistance in cells and tissues |
| US20040248799A1 (en) | 1993-05-27 | 2004-12-09 | Holaday John W. | Compositions and methods for treating cancer and hyperproliferative disorders |
| JP3759759B2 (ja) | 1994-03-04 | 2006-03-29 | 日本油脂株式会社 | リポソームおよび薬物運搬体 |
| US5540935A (en) | 1993-12-06 | 1996-07-30 | Nof Corporation | Reactive vesicle and functional substance-fixed vesicle |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| DE69526973T3 (de) | 1994-10-21 | 2010-01-07 | Innogenetics N.V. | Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel |
| US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
| US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
| US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| EP0975753A2 (en) | 1997-04-16 | 2000-02-02 | American Home Products Corporation | $g(b)-AMYLOID PEPTIDE-BINDING PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME |
| KR19990029749A (ko) | 1997-09-17 | 1999-04-26 | 미우라 아끼라 | 2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체 |
| JP4385152B2 (ja) | 1997-09-17 | 2009-12-16 | 三菱化学株式会社 | ２価反応性水溶性高分子誘導体及びそれを含有する複合体 |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6187335B1 (en) | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
| WO1999041279A2 (en) | 1998-02-13 | 1999-08-19 | Arch Development Corporation | Methods and compositions comprising the use of blocked b-amyloid peptide |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| US6025160A (en) | 1998-07-22 | 2000-02-15 | Smithkline Beecham Corporation | Polynucleotide and polypeptide sequences encoding rat mdr1b2 and screening methods thereof |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| ES2344189T3 (es) | 1999-09-03 | 2010-08-20 | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. | Agentes, composiciones y metodos que los utilizan utiles en el tratamiento o la prevencion de la enfermedad de alzheimer. |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US7442776B2 (en) | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| PT1259563E (pt) | 1999-12-22 | 2009-04-14 | Nektar Therapeutics Al Corp | Processo para a preparação de ésteres de 1-benzotriazolil- -carbonato de polímeros solúveis em água |
| US6521635B1 (en) | 2000-01-20 | 2003-02-18 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of MXR transport by acridine derivatives |
| US20030086938A1 (en) | 2000-02-21 | 2003-05-08 | Jensen Martin Roland | Novel methods for down-regulation of amyloid |
| JP2002047298A (ja) | 2000-07-10 | 2002-02-12 | Academia Sinica | 新規抗がん剤伝達系 |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| CA2418036A1 (en) | 2000-07-31 | 2002-02-07 | Yale University | Innate immune system-directed vaccines |
| WO2002017930A2 (en) | 2000-08-30 | 2002-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| WO2002021141A2 (en) | 2000-09-06 | 2002-03-14 | Aventis Pharma S.A. | Methods and compositions for diseases associated with amyloidosis |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| ES2228697T3 (es) | 2001-06-12 | 2005-04-16 | Wiltfang, Jens | Anticuerpo monoclonal, mab 1e8, que es especifico para los dos primeros aminoacidos de peptidos beta-amiloides y su utilizacion en la deteccion de peptidos beta-amiloides y/o sapp alfa. |
| ES2279869T3 (es) | 2001-06-20 | 2007-09-01 | Ramot At Tel Aviv University Ltd. | Peptido antigenico comprendido por mulitples copias de un epitope de un polipeptido implicado en enfermedades de formacion de placas y los procedimientos de uso correspondientes. |
| AU2002322720B2 (en) | 2001-07-25 | 2008-11-13 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| WO2003039467A2 (en) | 2001-11-02 | 2003-05-15 | Diagenics International Corporation | Monoclonal antibodies specific for beta-amyloid. |
| US20030229013A1 (en) | 2001-12-07 | 2003-12-11 | Shih-Kwang Wu | Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US20080233181A1 (en) | 2002-04-12 | 2008-09-25 | Nagy Jon O | Nanoparticle adjuvants for sub-unit vaccines |
| EP1523499A2 (en) | 2002-07-24 | 2005-04-20 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| AU2003302676A1 (en) | 2002-12-03 | 2004-06-23 | Blanchette Rockefeller Neurosciences Institute | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| WO2004058239A1 (en) | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| MXPA05008156A (es) | 2003-02-01 | 2005-09-30 | Neuralab Ltd | Inmunizacion activa para generar anticuerpos para beta-a soluble. |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| US20040242845A1 (en) | 2003-02-21 | 2004-12-02 | Nicolau Yves Claude | Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them |
| JP2007500218A (ja) | 2003-05-12 | 2007-01-11 | アフィーマックス・インコーポレイテッド | ポリ（エチレングリコール）修飾ペプチド系化合物の新規スペーサー部分 |
| FR2857875A1 (fr) | 2003-07-25 | 2005-01-28 | Univ Reims Champagne Ardenne | Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers |
| EP1663239A4 (en) | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER |
| RS54074B1 (sr) | 2004-02-20 | 2015-10-30 | Ac Immune Sa | Metode i kompozicije koje sadrže supramolekulske konstrukte |
| AU2005316503A1 (en) | 2004-12-17 | 2006-06-22 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
| MX2008007477A (es) | 2005-12-12 | 2008-09-03 | Ac Immune Sa | Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas. |
| SG172617A1 (en) | 2005-12-12 | 2011-07-28 | Ac Immune Sa | Therapeutic vaccine |
| TWI431014B (zh) | 2008-10-29 | 2014-03-21 | 中央研究院 | 腫瘤標靶胜肽及其於檢測及治療癌症之用途 |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція |
-
2011
- 2011-10-26 JP JP2013535421A patent/JP6027011B2/ja active Active
- 2011-10-26 AR ARP110103959A patent/AR083561A1/es not_active Application Discontinuation
- 2011-10-26 AU AU2011322553A patent/AU2011322553B2/en active Active
- 2011-10-26 US US13/881,502 patent/US9687447B2/en active Active
- 2011-10-26 TW TW100139025A patent/TW201223561A/zh unknown
- 2011-10-26 EP EP11775949.8A patent/EP2632434B1/en active Active
- 2011-10-26 CN CN201180051932.3A patent/CN103189050B/zh active Active
- 2011-10-26 WO PCT/EP2011/068797 patent/WO2012055933A1/en not_active Ceased
- 2011-10-26 KR KR1020137013183A patent/KR101854943B1/ko active Active
- 2011-10-26 CA CA2813833A patent/CA2813833C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2632434B1 (en) | Liposome-based construct comprising a peptide modified through hydrophobic moieties | |
| US12234265B2 (en) | Stabilized RSV F proteins and uses thereof | |
| AU2018269742B2 (en) | Nano-enabled immunotherapy in cancer | |
| TWI827557B (zh) | Ｔａｕ胜肽之組成物及其用途 | |
| US9289488B2 (en) | Vaccine engineering | |
| US20250319075A1 (en) | Phosphoserine containing compositions for immune tolerance induction | |
| WO2018017443A1 (en) | Immunogenic compositions and methods relating thereto | |
| JP2022116265A (ja) | 両親媒性化合物、新生抗原及び疎水性担体を含むワクチン組成物、並びにその使用方法 | |
| JP6416838B2 (ja) | ミエリン塩基性タンパク質のオリゴペプチドフラグメントを含有するリポソーム、医薬組成物および多発性硬化症の治療方法 | |
| AU2017218772A1 (en) | Cellular signalling inhibitors, their formulations and methods thereof | |
| JP4692983B2 (ja) | リポソーム封入物質がエンドソームから脱出可能なリポソーム | |
| CN111295200A (zh) | 作为疫苗中的佐剂的包含合成的神经节苷脂gm3变体的纳米颗粒 | |
| JP6014241B2 (ja) | ミエリン塩基性タンパク質のオリゴペプチドフラグメントを含有するリポソーム、医薬組成物および多発性硬化症の治療方法 | |
| US11701328B2 (en) | Phosphoserine containing compositions for immune tolerance induction | |
| Xu et al. | Modular assembly of lipid nanoparticles for targeted mrna therapeutics and vaccines | |
| EP4228692A1 (en) | Methods of treating diffuse large b-cell lymphoma | |
| HK1185262B (en) | Liposome-based construct comprising a peptide modified through hydrophobic moieties | |
| HK1185262A (en) | Liposome-based construct comprising a peptide modified through hydrophobic moieties | |
| Sun et al. | A Potent Athero-protective Nanovaccine Cocktail by Two-Pronged Intracellular Delivery of Antigen and Adjuvant for Dendritic Cell Activation |